Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase IV study of avalglucosidase alfa (Nexviazyme) in Chinese infants with Pompe disease (IOPD)
CTR20243998Phase 4Active
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of avalglucosidase alfa in Pompe disease, sponsored by Sanofi. Started May 2025; status: active.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on CTR20243998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243998.